01 · THE CUSTOMER PROBLEM
Delivery teams need a carrier whose binding strength, particle size, surface charge and release can be matched to the cargo and administration route.
ChitoGene provides a biodegradable carrier backbone with controllable MW, DDA, purity and functionalization for DNA, RNA and gene-editing cargo research.
Gene delivery performance begins with the molecular relationship between the carrier and its nucleic-acid cargo.
02 · RECOMMENDED STARTING POINT
Start with the material designed for the decision.
Chitosan provides a biodegradable, non-viral carrier architecture whose binding strength, size, surface charge and functional groups can be engineered around the cargo and delivery route.
Without the shell
Controlled fungal sourcing supports a traceable, non-animal supply strategy.
Specification engineered
MW, DDA, purity, charge density and format are selected around the target result.
Application ready
Powder is only the starting point; Mykito also develops films, fibers, gels, coatings and formulations.
One technical partner
Material selection, formulation support and the validation plan are connected from the first sample.
03 · PERFORMANCE TARGETS
Build toward outcomes a buyer can measure.
Cargo complexation
Positive amino groups bind negatively charged DNA and RNA to form protective polymer complexes.
Particle engineering
Molecular specification and formulation determine polyplex size, charge, stability and release.
Cellular uptake
Surface chemistry can be optimized for uptake while balancing cytocompatibility and cargo release.
Targeting strategies
Chitosan’s modifiable backbone supports ligand, PEG and other functional conjugation concepts.
04 · GO / NO-GO CRITERIA
Define the evidence before testing begins.
The first program is designed around three decision-making outputs—not an open-ended material trial.
N/P ratio and complex stability
Particle size, PDI and cargo release
Cellular uptake and cytocompatibility
05 · FROM SAMPLE TO DECISION
A practical application program,
not a bag of powder.
Define
Agree on the function, baseline, constraints and measurable success criteria.
Screen
Select the MW, DDA, purity, dose and physical format that fit the application.
Validate
Test the winning system in the finished formulation, device, process or use environment.
Recommended first request: An EndoFree carrier-grade MW/DDA matrix selected around the nucleic-acid cargo.
Start the Sample Brief06 · WHY CHITOSAN
Cationic complexation + matrix control
Protonated amino groups can interact with selected anionic actives, polymers and biological surfaces. MW, DDA, crosslinking and architecture then provide levers for adhesion, protection and release.
There is no universal concentration. Grade and dose are screened against pH, interacting ingredients, process conditions and the target performance profile.
Route-specific purity, residuals, compatibility, stability and regulatory suitability are established for the finished system.